Evidence map›Paper›PMID 32669099›Full record

ArticleBMC musculoskeletal disorders2020

Effectiveness of preemptive antifibrinolysis with tranexamic acid in rheumatoid arthritis patients undergoing total knee arthroplasty: a study protocol for a randomized controlled trial.

Yiting Lei, Jiacheng Liu, Xi Liang, Ning Hu, Fuxing Pei, Wei Huang

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yiting LeiDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Jiacheng LiuDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xi LiangDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ning HuDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Fuxing PeiDepartment of Orthopedics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Wei HuangDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. huangw511@163.com.ORCID http://orcid.org/0000-0001-6717-3748
The Affiliated Yongchuan Hospital of Chongqing Medical University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with rheumatoid arthritis (RA) who have undergone total knee arthroplasty are at increased risk of requiring a blood transfusion. This study is designed to compare the effects of preemptive antifibrinolysis of single-dose and repeat-dose tranexamic acid (TXA) in in RA patients undergoing total knee arthroplasty (TKA). METHODS/

designThe study will be a double-blind randomized controlled trial with two parallel groups of RA patients. Group A will be given 100 ml normal saline twice daily starting from 3 days before the operation, Group B will be given TXA 1.5 g twice daily starting from 3 days before the operation. All patients will be given TXA 1.5 g 30 min before the operation. The primary outcomes will be evaluated with total blood loss and hidden blood loss. Other outcome measurements such as, fibrinolysis parameters, inflammatory factors, visual analogue scale for post-operative pain, analgesia usage, coagulation parameters, transfusion, the length of stay (LOS), total hospitalization costs, the incidence of thromboembolic events and other complications will be recorded and compared. Recruitment is scheduled to begin on 1 August 2020, and the study will continue until 31 May 2021. DISCUSSION: In current literature there is a lack of evidence with regard to the efficacy of TXA in RA patients. The findings of this study, whether positive or negative, will contribute to the formulation of further recommendations on the use of TXA in RA patients undergoing TKA.

trial registrationChinese Clinical Trial Registry, ChiCTR2000029720 . Registered 14 February 2020.

Indexed as

Antifibrinolytic AgentsArthritis, RheumatoidArthroplasty, Replacement, KneeTranexamic AcidAdministration, IntravenousBlood Loss, SurgicalHumansPostoperative HemorrhageRandomized Controlled Trials as TopicAntifibrinolytic AgentsTranexamic AcidPreemptive antifibrinolysisRheumatoid arthritisTranexamic acid, Total knee arthroplasty

Identifiers

PMID32669099
PMCPMC7362400
OpenAlexW3043143575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.